Simon Rebecca, Yang Sophia, Hameed Afshan B
Irvine Department of Obstetrics and Gynecology, University of California, Orange, California.
AJP Rep. 2018 Oct;8(4):e335-e342. doi: 10.1055/s-0038-1675832. Epub 2018 Nov 21.
This study is to review published cases of peripartum cardiomyopathy (PPCM) treated with bromocriptine and outline pros and cons of the treatment strategy. Data were collected from PubMed/MedLine, ClinicalTrials.gov; the years 2007 to 2018 were searched for English-language articles. Search terms: "bromocriptine and peripartum cardiomyopathy", "bromocriptine and cardiomyopathy." This search strategy yielded 171 articles. After excluding duplicates, 86 studies were reviewed. Sixty-one articles involving the treatment of PPCMP were included, and of these, 17 were case reports of patients with PPCMP treated with bromocriptine; these studies were included in this review. Seventeen of these articles were case reports of patients with peripartum cardiomyopathy treated with bromocriptine that were included. Bromocriptine seems to be a promising treatment, there is currently insufficient evidence for universal utilization of bromocriptine for all patients with PPCMP. Addition of bromocriptine to the standard heart failure therapy should be individualized.
本研究旨在回顾已发表的用溴隐亭治疗围产期心肌病（PPCM）的病例，并概述该治疗策略的利弊。数据收集自PubMed/MedLine、ClinicalTrials.gov；检索了2007年至2018年的英文文章。检索词：“溴隐亭与围产期心肌病”、“溴隐亭与心肌病”。该检索策略产生了171篇文章。排除重复项后，对86项研究进行了综述。纳入了61篇涉及围产期心肌病治疗的文章，其中17篇是用溴隐亭治疗围产期心肌病患者的病例报告；这些研究被纳入本综述。其中17篇文章是用溴隐亭治疗围产期心肌病患者的病例报告，被纳入其中。溴隐亭似乎是一种有前景的治疗方法，但目前尚无足够证据支持对所有围产期心肌病患者普遍使用溴隐亭。在标准心力衰竭治疗中添加溴隐亭应个体化。
